MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Retrieved on:
Friday, September 3, 2021
JD/MBA, Private Securities Litigation Reform Act, Patient, Form 8-K, Form 10-K, MD, U.S. Securities and Exchange Commission, Neurodegeneration, Substance dependence, ALS, Annual report, Multiple sclerosis, Failure, Nasdaq, Risk, Security (finance), Morgan Stanley, Intellectual property, Tokyo Stock Exchange, Doctor of Philosophy, Fatty liver disease, MS, FDA, Idiopathic pulmonary fibrosis, Code, NASH, Glioblastoma, DCM, GLOBE, Amyotrophic lateral sclerosis, IPF, NASDAQ, Pharmaceutical industry
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced thatMediciNovawill participate in thevirtual Morgan Stanley 19th Annual Global Healthcare Conferencewhich will be held fromSeptember 9 - 15, 2021.
Key Points:
- LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced thatMediciNovawill participate in thevirtual Morgan Stanley 19th Annual Global Healthcare Conferencewhich will be held fromSeptember 9 - 15, 2021.
- MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
- Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development.
- MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.